Garage AI-Designed Schizophrenia Drug Draws Regulatory Skepticism

A solo biochemist claims to have designed via ChatGPT and synthesized PAC-3310, a schizophrenia drug, in a garage, modeling it after a recently approved antipsychotic. Experts emphasize that drug development requires extensive preclinical work and a costly, multi-year FDA process, making DIY creation and testing highly unlikely to reach approval and highlighting risks of overreliance on AI for complex therapeutics.